Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice Regarding the Absorption-Type Merger of Torii Pharmaceutical Co., Ltd., a Wholly Owned Subsidiary
Shionogi, Last Fiscal Year Dividend Revised Upward by 5 Yen
Notice of Revisions to Dividend Forecasts (Dividend Increase)
StemRIM rises for fourth straight session after completing patient enrollment in Phase 1/2 trial
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
GSK, Pfizer and Shionogi complete changes to ViiV Healthcare shareholding
Notice Regarding Bridge Loan Financing in Connection with an Additional Investment in ViiV Healthcare Ltd
Notice Regarding the Consolidation of Shionogi Apnimed Sleep Science, LLC as a Subsidiary of Shionogi
Notice regarding the Bridge Loan Financing Related to Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS and IV RAD
Shionogi Announces Approval in Japan of a Supplemental Indication for XOCOVA(Ensitrelvir Fumaric Acid) for the Post-Exposure Prophylaxis of COVID-19
Application for Manufacturing and Marketing Approval of a New Lotion Formulation for the Atopic Dermatitis Treatment "CORECTIM" in Japan
Notice Regarding the Determination of the Basic Policy for the Absorption-Type Merger of TORII PHARMACEUTICAL Co., Ltd.
Shionogi, Apr-Dec (Cumulative 3Q) Net Income Increases by 18%, Oct-Dec Net Income Increases by 47%
Consolidated Financial Results for the Third Quarter of Fiscal Year 2025 (IFRS)
Financial Results for the 3rd Quarter of FY2025 Supplement
3rd Quarter of Fiscal 2025 Financial Results
[Summary]GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding
Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS (edaravone) and IV RADIC
Shionogi Receives Approval in Japan to Manufacture and Market ZURZUVAE Capsules 30 mg for the Treatment of Major Depressive Disorder
Notice regarding Completion of Succession of Japan Tobacco Inc.’s Pharmaceutical Business through Simplified Absorption-Type Company Split